文献速递免疫规划卫生政策与健康促进

美国成人中三抗原疫苗与单抗原疫苗预防乙型肝炎的成本效果比较

Cost-effectiveness of a 3-antigen versus single-antigen vaccine for the prevention of hepatitis B in adults in the United States.
PubMed 文献 · Vaccine · 2023-05-03

该研究用决策树与马尔可夫模型随访10万名美国成人至终生,比较三抗原疫苗(PreHevbrio™)与单抗原疫苗(Engerix-B™)预防HBV感染的成本效果。三抗原疫苗在18-64岁成人、糖尿病及肥胖成人中为优势策略,在≥65岁成人中成本效果为每获得1个QALY增加26237美元。

要点

  • 三抗原疫苗在18-64岁成人、糖尿病及肥胖成人中健康产出更优且成本更低(优势策略)。
  • ≥65岁成人中三抗原疫苗成本效果为每获得1个QALY增加26237美元,低于常用支付意愿阈值。
  • 敏感性分析显示结果对每剂疫苗成本、发病率和接种年龄敏感。

核心结论

  • 新获批的三抗原疫苗是预防美国成人HBV感染、应对长期乙型肝炎负担的成本节约或成本有效干预。

研究设计与样本

  • 采用决策树与马尔可夫组合模型,随访10万名接种三抗原或单抗原疫苗的美国成人至终生。
  • 从社会与医疗部门视角,对18-44岁、45-64岁、≥65岁成人、糖尿病成人及肥胖成人计算结局。
  • 血清保护率取自3期头对头PROTECT试验(NCT03393754)。
  • 健康结局与成本(2020美元)按每年3%贴现。
  • 开展单因素敏感性分析与情景分析。

主要发现

  • 模型中,三抗原疫苗在所有建模人群中较单抗原疫苗导致更少HBV感染、并发症和死亡,归因于更高的血清保护率与更快的起效。
  • 与单抗原疫苗相比,三抗原疫苗在18-64岁成人、糖尿病成人及肥胖成人中健康结局更好、QALY更多且成本更低(优势策略)。
  • ≥65岁成人中,三抗原疫苗较单抗原疫苗成本效果为每获得1个QALY增加26237美元,低于常用支付意愿阈值(每QALY 50000-100000美元)。
  • 敏感性分析中,结果对每剂疫苗成本、发病率和接种年龄敏感。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The first 3-antigen hepatitis B vaccine was approved by the United States (US) Food and Drug Administration in November 2021 and was recommended by the Centers for Disease Control and Prevention in 2022. We estimated the cost-effectiveness of this 3-antigen vaccine (PreHevbrio™) relative to the single-antigen vaccine, Engerix-BTM, to prevent hepatitis B virus (HBV) infection among US adults. METHODS: A cost-effectiveness model was developed using a combined decision-tree and Markov structure to follow 100,000 adults over their remaining lifetimes after vaccination with either the 3-antigen or single-antigen vaccine. Outcomes from societal and healthcare sector perspectives were calculated for adults aged 18-44, 45-64, and ≥65 years; adults with diabetes; and adults with obesity. Seroprotection rates were obtained from the phase3, head-to-head PROTECT trial (NCT03393754). Incidence, vaccine costs, vaccine adherence rates, direct and indirect costs, utilities, transition probabilities, and mortality were obtained from published sources. Health outcomes and costs (2020USD) were discounted 3% annually and reported by vaccine and population. One-way sensitivity and scenario analyses were conducted. RESULTS: In the model, the 3-antigen vaccine led to fewer HBV infections, complications, and deaths compared with the single-antigen vaccine in all modeled populations due to higher rates and faster onset of seroprotection. Compared with the single-antigen vaccine, the 3-antigen vaccine had better health outcomes, more quality-adjusted life-years (QALYs), and lower costs in adults aged 18-64 years, adults with diabetes, and adults with obesity (dominant strategy). For adults aged ≥65 years, the 3-antigen vaccine was cost-effective compared with the single-antigen vaccine ($26,237/QALY gained) below common willingness-to-pay thresholds ($50,000-$100,000/QALY gained). In sensitivity analyses, results were sensitive to vaccine cost per dose, incidence, and age at vaccination. CONCLUSION: The recently approved 3-antigen vaccine is a cost-saving or cost-effective intervention for preventing HBV infection and addressing the long-standing burden of hepatitis B among US adults.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Talbird SE, Anderson SA, Nossov M, et al. Cost-effectiveness of a 3-antigen versus single-antigen vaccine for the prevention of hepatitis B in adults in the United States. Vaccine. 2023. PMID: 37147201. doi:10.1016/j.vaccine.2023.04.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。